Literature DB >> 32518112

Cerebral amyloid angiopathy-linked β-amyloid mutations promote cerebral fibrin deposits via increased binding affinity for fibrinogen.

Steven A Cajamarca1, Erin H Norris1, Louise van der Weerd2,3, Sidney Strickland1, Hyung Jin Ahn4,5.   

Abstract

Cerebral amyloid angiopathy (CAA), where beta-amyloid (Aβ) deposits around cerebral blood vessels, is a major contributor of vascular dysfunction in Alzheimer's disease (AD) patients. However, the molecular mechanism underlying CAA formation and CAA-induced cerebrovascular pathology is unclear. Hereditary cerebral amyloid angiopathy (HCAA) is a rare familial form of CAA in which mutations within the (Aβ) peptide cause an increase in vascular deposits. Since the interaction between Aβ and fibrinogen increases CAA and plays an important role in cerebrovascular damage in AD, we investigated the role of the Aβ-fibrinogen interaction in HCAA pathology. Our work revealed the most common forms of HCAA-linked mutations, Dutch (E22Q) and Iowa (D23N), resulted in up to a 50-fold stronger binding affinity of Aβ for fibrinogen. In addition, the stronger interaction between fibrinogen and mutant Aβs led to a dramatic perturbation of clot structure and delayed fibrinolysis. Immunofluorescence analysis of the occipital cortex showed an increase of fibrin(ogen)/Aβ codeposition, as well as fibrin deposits in HCAA patients, compared to early-onset AD patients and nondemented individuals. Our results suggest the HCAA-type Dutch and Iowa mutations increase the interaction between fibrinogen and Aβ, which might be central to cerebrovascular pathologies observed in HCAA.

Entities:  

Keywords:  fibrinogen; fibrinolysis; hereditary cerebral amyloid angiopathy; β-amyloid

Year:  2020        PMID: 32518112      PMCID: PMC7322009          DOI: 10.1073/pnas.1921327117

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  35 in total

1.  White matter hyperintensities are a core feature of Alzheimer's disease: Evidence from the dominantly inherited Alzheimer network.

Authors:  Seonjoo Lee; Fawad Viqar; Molly E Zimmerman; Atul Narkhede; Giuseppe Tosto; Tammie L S Benzinger; Daniel S Marcus; Anne M Fagan; Alison Goate; Nick C Fox; Nigel J Cairns; David M Holtzman; Virginia Buckles; Bernardino Ghetti; Eric McDade; Ralph N Martins; Andrew J Saykin; Colin L Masters; John M Ringman; Natalie S Ryan; Stefan Förster; Christoph Laske; Peter R Schofield; Reisa A Sperling; Stephen Salloway; Stephen Correia; Clifford Jack; Michael Weiner; Randall J Bateman; John C Morris; Richard Mayeux; Adam M Brickman
Journal:  Ann Neurol       Date:  2016-04-27       Impact factor: 10.422

Review 2.  Molecular mechanisms of initiation of fibrinolysis by fibrin.

Authors:  Leonid Medved; Willem Nieuwenhuizen
Journal:  Thromb Haemost       Date:  2003-03       Impact factor: 5.249

3.  Biochemical and structural analysis of the interaction between β-amyloid and fibrinogen.

Authors:  Daria Zamolodchikov; Hanna E Berk-Rauch; Deena A Oren; Daniel S Stor; Pradeep K Singh; Masanori Kawasaki; Kazuyoshi Aso; Sidney Strickland; Hyung Jin Ahn
Journal:  Blood       Date:  2016-07-07       Impact factor: 22.113

Review 4.  The cerebral beta-amyloid angiopathies: hereditary and sporadic.

Authors:  Sandy X Zhang-Nunes; Marion L C Maat-Schieman; Sjoerd G van Duinen; Raymund A C Roos; Matthew P Frosch; Steven M Greenberg
Journal:  Brain Pathol       Date:  2006-01       Impact factor: 6.508

Review 5.  Vascular risk factors and dementia: how to move forward?

Authors:  Anand Viswanathan; Walter A Rocca; Christophe Tzourio
Journal:  Neurology       Date:  2009-01-27       Impact factor: 9.910

Review 6.  Genetics and molecular pathogenesis of sporadic and hereditary cerebral amyloid angiopathies.

Authors:  Tamas Revesz; Janice L Holton; Tammaryn Lashley; Gordon Plant; Blas Frangione; Agueda Rostagno; Jorge Ghiso
Journal:  Acta Neuropathol       Date:  2009-02-19       Impact factor: 17.088

Review 7.  Fibrinogen and altered hemostasis in Alzheimer's disease.

Authors:  Marta Cortes-Canteli; Daria Zamolodchikov; Hyung Jin Ahn; Sidney Strickland; Erin H Norris
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

8.  Examination of the clinicopathologic continuum of Alzheimer disease in the autopsy cohort of the National Alzheimer Coordinating Center.

Authors:  Alberto Serrano-Pozo; Jing Qian; Sarah E Monsell; Matthew P Frosch; Rebecca A Betensky; Bradley T Hyman
Journal:  J Neuropathol Exp Neurol       Date:  2013-12       Impact factor: 3.685

9.  Early role of vascular dysregulation on late-onset Alzheimer's disease based on multifactorial data-driven analysis.

Authors:  Y Iturria-Medina; R C Sotero; P J Toussaint; J M Mateos-Pérez; A C Evans
Journal:  Nat Commun       Date:  2016-06-21       Impact factor: 14.919

10.  Fibrinogen-induced perivascular microglial clustering is required for the development of axonal damage in neuroinflammation.

Authors:  Dimitrios Davalos; Jae Kyu Ryu; Mario Merlini; Kim M Baeten; Natacha Le Moan; Mark A Petersen; Thomas J Deerinck; Dimitri S Smirnoff; Catherine Bedard; Hiroyuki Hakozaki; Sara Gonias Murray; Jennie B Ling; Hans Lassmann; Jay L Degen; Mark H Ellisman; Katerina Akassoglou
Journal:  Nat Commun       Date:  2012       Impact factor: 14.919

View more
  9 in total

1.  Aβ peptide and fibrinogen weave a web of destruction in cerebral amyloid angiopathy.

Authors:  Woosuk S Hur; Matthew J Flick
Journal:  Proc Natl Acad Sci U S A       Date:  2020-06-23       Impact factor: 11.205

2.  Predicting mortality among ischemic stroke patients using pathways-derived polygenic risk scores.

Authors:  Jiang Li; Durgesh Chaudhary; Christoph J Griessenauer; David J Carey; Ramin Zand; Vida Abedi
Journal:  Sci Rep       Date:  2022-07-19       Impact factor: 4.996

Review 3.  Hemostasis components in cerebral amyloid angiopathy and Alzheimer's disease.

Authors:  Nicole Ziliotto; Francesco Bernardi; Fabrizio Piazza
Journal:  Neurol Sci       Date:  2021-05-27       Impact factor: 3.307

Review 4.  Alzheimer's Disease-Rationales for Potential Treatment with the Thrombin Inhibitor Dabigatran.

Authors:  Klaus Grossmann
Journal:  Int J Mol Sci       Date:  2021-04-30       Impact factor: 5.923

5.  The contact activation system and vascular factors as alternative targets for Alzheimer's disease therapy.

Authors:  Pradeep K Singh; Ana Badimon; Zu-Lin Chen; Sidney Strickland; Erin H Norris
Journal:  Res Pract Thromb Haemost       Date:  2021-05-03

6.  The Correlations Between Plasma Fibrinogen With Amyloid-Beta and Tau Levels in Patients With Alzheimer's Disease.

Authors:  Dong-Yu Fan; Hao-Lun Sun; Pu-Yang Sun; Jie-Ming Jian; Wei-Wei Li; Ying-Ying Shen; Fan Zeng; Yan-Jiang Wang; Xian-Le Bu
Journal:  Front Neurosci       Date:  2021-01-21       Impact factor: 4.677

7.  Fibrin-targeting molecular MRI in inflammatory CNS disorders.

Authors:  Johannes Lohmeier; Rafaela V Silva; Anna Tietze; Matthias Taupitz; Takaaki Kaneko; Harald Prüss; Friedemann Paul; Carmen Infante-Duarte; Bernd Hamm; Peter Caravan; Marcus R Makowski
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-05-04       Impact factor: 10.057

Review 8.  Direct Oral Anticoagulants (DOACs) for Therapeutic Targeting of Thrombin, a Key Mediator of Cerebrovascular and Neuronal Dysfunction in Alzheimer's Disease.

Authors:  Klaus Grossmann
Journal:  Biomedicines       Date:  2022-08-04

9.  Anticoagulants for Treatment of Alzheimer's Disease.

Authors:  Klaus Grossmann
Journal:  J Alzheimers Dis       Date:  2020       Impact factor: 4.472

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.